Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab phase 1/2 study in advanced solid tumors
NL-OMON56321Phase 2Recruiting
- Sponsor
- Merus
- Start
- May 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of petosemtamab in Nonhematologic neoplasms, colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), Anogenital Squamous Cell Carcinoma, cutaneous squamous cell carcinoma (cSCC), sponsored by Merus. Started May 2023; status: recruiting.
02
Drugs
petosemtamab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)Anogenital Squamous Cell Carcinomacutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON56321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56321.